Mallinckrodt Pharmaceuticals
GPTKB entity
Statements (73)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:CuraGen_Corporation
gptkb:Questcor_Pharmaceuticals gptkb:Ivenix,_Inc. gptkb:Therakos,_Inc. 2014 2014-10-01 $5.6 billion Ivenix Mallinckrodt_Baker_Inc. |
| gptkbp:canLeadTo |
Michael J. McGowan
|
| gptkbp:CEO |
gptkb:R._Scott_Smith
gptkb:Mark_Trudeau |
| gptkbp:clinicalTrials |
Cancer
Multiple sclerosis Autoimmune diseases Chronic pain Neuropathic pain |
| gptkbp:employees |
~3,000
|
| gptkbp:filingCountry |
2020
|
| gptkbp:focusArea |
Immunology
Pain management Neurology Rare diseases |
| gptkbp:founded |
1867
|
| gptkbp:headCoach |
3,000
~3,000 (2021) |
| gptkbp:headquarters |
gptkb:St._Louis
gptkb:United_States gptkb:St._Louis,_Missouri |
| https://www.w3.org/2000/01/rdf-schema#label |
Mallinckrodt Pharmaceuticals
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:legalStatus |
Bankruptcy proceedings
Opioid crisis Litigation settlements |
| gptkbp:market |
$1.2 billion (2021)
$1.1 billion (2021) |
| gptkbp:mayHave |
gptkb:David_M._H._Houghton
|
| gptkbp:notableEvent |
gptkb:H.P._Acthar_Gel
gptkb:Ofirmev gptkb:Therakos Xartemis XR Bankruptcy filing (2020) Launch of H.P. Acthar Gel (2001) Launch of Ofirmev (2010) Restructuring plan (2021) Settlement of opioid litigation (2021) Acquisition_of_Ivenix_(2021) Acquisition_of_Questcor_(2014) Launch_of_Therakos_(2017) Launch_of_Xartemis_XR_(2014) |
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer gptkb:Teva_Pharmaceuticals gptkb:Horizon_Therapeutics gptkb:Amgen gptkb:Sandoz |
| gptkbp:philanthropy |
Research funding
Disaster relief efforts Health education programs Community health initiatives Patient assistance programs |
| gptkbp:products |
Specialty pharmaceuticals
|
| gptkbp:reform |
Chapter_11
|
| gptkbp:researchFocus |
Biologics
Controlled substances Generics Specialty drugs |
| gptkbp:revenue |
$2.5 billion (2020)
|
| gptkbp:stockSymbol |
MNK
|
| gptkbp:subsidiary |
gptkb:Mallinckrodt_LLC
|
| gptkbp:tradedOn |
gptkb:NYSE
|
| gptkbp:website |
www.mallinckrodt.com
|